Skip to main content

Table 1 Distribution of the reviews by Cochrane groups

From: An investigation of the constancy of effect in Cochrane systematic reviews in context with the assumptions for noninferiority trials

Cochrane group

Frequency

Pain, Palliative and Supportive Care Group

22.0 (9.3%)

Pregnancy and Childbirth Group

20.0 (8.5%)

Gynaecology and fertility group

15.0 (6.4%)

Heart Group

13.0 (5.5%)

Anaesthesia, Critical and Emergency Care Group

11.0 (4.7%)

IBD Group

11.0 (4.7%)

Musculoskeletal Group

10.0 (4.2%)

Stroke Group

9.0 (3.8%)

Kidney and Transplant Group

9.0 (3.8%)

Airway group

8.0 (3.4%)

Hypertension Group

8.0 (3.4%)

Acute Respiratory Infections Group

7.0 (3.0%)

Infectious Disease Group

7.0 (3.0%)

Vascular Group

7.0 (3.0%)

Common Mental Disorders Group

6.0 (2.5%)

Drugs and Alcohol Group

5.0 (2.1%)

ENT Group

5.0 (2.1%)

Neonatal Group

5.0 (2.1%)

Neuromuscular group

5.0 (2.1%)

Schizophrenia Group

5.0 (2.1%)

Skin Group

5.0 (2.1%)

Upper GI and Pancreatic Diseases Group

5.0 (2.1%)

Developmental, Psychosocial and Learning Problems Group

3.0 (1.3%)

Epilepsy Group

3.0 (1.3%)

Wounds Group

3.0 (1.3%)

Hepato-Biliary Group

3.0 (1.3%)

Tobacco Addiction Group

3.0 (1.3%)

Bone, Joint and Muscle Trauma Group

2.0 (0.8%)

Cystic Fibrosis and Genetic Disorders Group

2.0 (0.8%)

Dementia and Cognitive Improvement Group

2.0(0.8%)

Eye and Vision Group

2.0 (0.8%)

Haematological Malignancies Group

2.0 (0.8%)

Incontinence Group

2.0 (0.8%)

Metabolic and Endocrine Disorders Group

2.0 (0.8%)

Movement Disorders Group

2.0 (0.8%)

Other groups

7.0 (3.0%)

Total

236.0 (100.0%)

  1. IBD inflammatory bowel disease